Johnson & Johnson's niraparib combo significantly delays prostate cancer progression in HRR-altered patients with strong ...

Johnson & Johnson (NYSE:JNJ) recently announced promising Phase 1 study results for Pasritamig, a novel antibody for advanced ...

See here for 5 large-cap, dividend-paying stocks with significant discounts. Click for our cutdown of dividend stocks using ...

JNJ-79635322 shows favorable responses and manageable safety in BCMA/GPRC5D-naïve patients with relapsed/refractory multiple ...

Johnson & Johnson shows strong profitability and solid value, but faces growth uncertainty, legal risks, and pricing ...

Johnson & Johnson JNJ announced positive top-line data from a late-stage study evaluating the combination of niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, plus ...

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Multi-Factor Investor model based on the published strategy ...

Johnson & Johnson shared positive ASCO 2025 results, including improved survival and remission in prostate and multiple ...

JNJ-5322 is designed to target three distinct proteins, aiming to improve treatment outcomes by addressing tumor heterogeneity and reducing resistance development. The trial involved 126 heavily ...

Dr. Jared Weiss details the importance of continued research into novel therapies for patients with lung cancer.

Rarely do any stocks hold up during a recession, and those that do aren’t guaranteed to do so in the next one. Recessions ...